Sign In
Buy OCUP
$1.17
+0 (+0%)
At Close: Jan 22, 2025
Ocuphire Announces Addition to the Russell Microcap® Index
07:30am, Friday, 11'th Jun 2021
FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of t
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
04:10pm, Tuesday, 08'th Jun 2021
Capital Raise Expected to Extend Runway Through Late 2022 and Allow Additional Milestones for a Potential NDA Filing for Nyxol in Reversal of Mydriasis Capital Raise Expected to Extend Runway Through
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
09:04am, Friday, 04'th Jun 2021
FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi
Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
01:35am, Thursday, 13'th May 2021
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients
10:43am, Thursday, 08'th Apr 2021
Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic reti
Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
08:31am, Thursday, 08'th Apr 2021
APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy
Ocuphire Pharma Stock Price: $25 Target By Alliance Global Partners
08:14am, Monday, 05'th Apr 2021
The shares of Ocuphire Pharma Inc (NASDAQ: OCUP) have increased by over 10% pre-market. This is why it happened.
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:10pm, Thursday, 01'st Apr 2021
FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely
OCUP Stock Price Increases Over 90% Pre-Market: Why It Happened
06:53am, Monday, 15'th Mar 2021
The stock price of Ocuphire Pharma, Inc. (Nasdaq: OCUP) is trading at over 90% pre-market as of 6:47 AM ET today. This is why it happened.
Ocuphire Pharma Stock Is Trading Higher After Nyxol Aces Late-Stage Study
06:38am, Monday, 15'th Mar 2021
Ocuphire Pharma Inc (NASDAQ: OCUP) stock is soaring in the premarket in reaction to positive data from MIRA-2 Phase 3 trial evaluating Nyxol. Nyxol is an eye drop formulation of phentolamine mes
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
06:00am, Monday, 15'th Mar 2021
Nyxol Meets Its Primary and Multiple Secondary Endpoints Including Statistically Significant Efficacy Returning Subjects More Rapidly to Normal Pupil Size Across a Breadth of Dilating Agents and Iris
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
04:30pm, Wednesday, 10'th Mar 2021
FARMINGTON HILLS, Mich., March 10, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap
Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design
Ocuphire to Participate in March Investor Conferences
08:27am, Thursday, 04'th Mar 2021
HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th Oppenheimer Healthcare Conference at 9:20 am ET on March 18th
